Skip to main content

Unique probiotic concept for women is launched in India. Positive reactions from medical community

Press Release   •   Mar 20, 2006 15:00 GMT

Chr. Hansen A/S recently licensed Tablets (India) Ltd. as the exclusive working partner in India for Urex ? a unique probiotic concept for women's health.

Urex is the only oral probiotic concept clinically documented to restore and maintain a healthy vaginal flora and reduce the risk of urogenital infections.

The Urex concept is based on the world's most documented probiotic strains for women's health: Lactobacillus Rhamnosus GR-1? and Lactobacillus Reuteri RC-14?, licensed from Urex Biotech Inc. It is produced and marketed globally by Chr. Hansen, the world leader in probiotics.

?The licensing of Tablets India is a significant step in our company's strategy to commercialize the Urex concept on a global scale and be the leading supplier of probiotic concepts for women's health. Tablets India is a highly professional company with a strong market presence in the Indian pharmaceutical market particularly in the field of probiotics and we have very high expectations to this partnership,? said Steen Andersen, Vice President for Chr. Hansen's Human Health & Nutrition Business Unit.

Presented to leading doctors

A few weeks ago Tablets India introduced for the first time in India this concept under the brand name of Ecoflora?. As part of the market launch activities, Dr. Gregor Reid, international expert on probiotics and co-inventor of the technology, presented the scientific and clinical evidence on Ecoflora? to the Indian medical community. Dr. Reid spoke at the All India Congress of Obstetrics and Gynecologists in Cochin and later to more than 1000 leading gynecologists through a series of scientific lectures in Chennai, Hyderabad, Calcutta, Mumbai, Agra and Delhi.

It is truly rewarding to experience how more than 20 years of dedicated probiotic research within women's health is now being translated into a commercial product that can help women all over the world. It is clear that the medical community in India is quite positive and open toward the use of probiotics and I see a great future for Ecoflora? in India,? said Dr. Gregor Reid, Urex Biotech.

Opportunities in partnership

Ecoflora? is manufactured and marketed throughout India to doctors and pharmacies by Tablet India's own large, specialized sales force.

?We are very excited about our partnership with Chr. Hansen and the opportunity to utilize Tablets India's expertise and market presence in the area of probiotics. The introduction of Ecoflora? will consolidate our position as a leading manufacturer and marketer of unique probiotics in India. With the launching of this new concept we have great opportunities to improve the quality of life of Indian women,? said Mr. R.K. Jhaver, CEO of Tablets India Limited.

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in over 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen.

Comments (0)

Add comment